Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease

The incidence of inflammatory bowel diseases (IBD) is rising worldwide. The therapeutic options for IBD are expanding, and the number of drugs with new targets will rapidly increase in coming years. A rapid step-up approach with close monitoring of intestinal inflammation is extensively used. The fe...

Descripción completa

Detalles Bibliográficos
Autores principales: Tran-Minh, My-Linh, Sousa, Paula, Maillet, Marianne, Allez, Matthieu, Gornet, Jean-Marc
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424291/
https://www.ncbi.nlm.nih.gov/pubmed/28539989
http://dx.doi.org/10.4254/wjh.v9.i13.613
_version_ 1783235100316532736
author Tran-Minh, My-Linh
Sousa, Paula
Maillet, Marianne
Allez, Matthieu
Gornet, Jean-Marc
author_facet Tran-Minh, My-Linh
Sousa, Paula
Maillet, Marianne
Allez, Matthieu
Gornet, Jean-Marc
author_sort Tran-Minh, My-Linh
collection PubMed
description The incidence of inflammatory bowel diseases (IBD) is rising worldwide. The therapeutic options for IBD are expanding, and the number of drugs with new targets will rapidly increase in coming years. A rapid step-up approach with close monitoring of intestinal inflammation is extensively used. The fear of side effects represents one the most limiting factor of their use. Despite a widespread use for years, drug induced liver injury (DILI) management remains a challenging situation with Azathioprine and Methotrexate. DILI seems less frequent with anti-tumor necrosis factor agents and new biologic therapies. The aim of this review is to report incidence, physiopathology and practical guidelines in case of DILI occurrence with the armamentarium of old and new drugs in the field of IBD.
format Online
Article
Text
id pubmed-5424291
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-54242912017-05-24 Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease Tran-Minh, My-Linh Sousa, Paula Maillet, Marianne Allez, Matthieu Gornet, Jean-Marc World J Hepatol Review The incidence of inflammatory bowel diseases (IBD) is rising worldwide. The therapeutic options for IBD are expanding, and the number of drugs with new targets will rapidly increase in coming years. A rapid step-up approach with close monitoring of intestinal inflammation is extensively used. The fear of side effects represents one the most limiting factor of their use. Despite a widespread use for years, drug induced liver injury (DILI) management remains a challenging situation with Azathioprine and Methotrexate. DILI seems less frequent with anti-tumor necrosis factor agents and new biologic therapies. The aim of this review is to report incidence, physiopathology and practical guidelines in case of DILI occurrence with the armamentarium of old and new drugs in the field of IBD. Baishideng Publishing Group Inc 2017-05-08 2017-05-08 /pmc/articles/PMC5424291/ /pubmed/28539989 http://dx.doi.org/10.4254/wjh.v9.i13.613 Text en ©The Author(s) 2017. Published by Baishideng Publishing Group Inc. All rights reserved. http://creativecommons.org/licenses/by-nc/4.0/ This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial.
spellingShingle Review
Tran-Minh, My-Linh
Sousa, Paula
Maillet, Marianne
Allez, Matthieu
Gornet, Jean-Marc
Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease
title Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease
title_full Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease
title_fullStr Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease
title_full_unstemmed Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease
title_short Hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease
title_sort hepatic complications induced by immunosuppressants and biologics in inflammatory bowel disease
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5424291/
https://www.ncbi.nlm.nih.gov/pubmed/28539989
http://dx.doi.org/10.4254/wjh.v9.i13.613
work_keys_str_mv AT tranminhmylinh hepaticcomplicationsinducedbyimmunosuppressantsandbiologicsininflammatoryboweldisease
AT sousapaula hepaticcomplicationsinducedbyimmunosuppressantsandbiologicsininflammatoryboweldisease
AT mailletmarianne hepaticcomplicationsinducedbyimmunosuppressantsandbiologicsininflammatoryboweldisease
AT allezmatthieu hepaticcomplicationsinducedbyimmunosuppressantsandbiologicsininflammatoryboweldisease
AT gornetjeanmarc hepaticcomplicationsinducedbyimmunosuppressantsandbiologicsininflammatoryboweldisease

Ejemplares similares